Drug profile · INN
simeprevir sodium
SOVRIAD
simeprevir sodium (SOVRIAD) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — simeprevir sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
simeprevir sodium (SOVRIAD) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Primary target: Hepatitis C virus serine protease, NS3/NS4A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is simeprevir sodium?
simeprevir sodium (SOVRIAD) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for simeprevir sodium?
SOVRIAD is a marketed brand name for simeprevir sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of simeprevir sodium?
simeprevir sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.